Bilayer Tablet Segmentation for Drug Compatibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The combination of telmisartan and hydrochlorothiazide in conventional fixed-dose combination drugs faces challenges due to incompatibility issues and reduced dissolution rates, leading to stability and compliance problems, particularly with telmisartan's poor solubility and hydrochlorothiazide's interaction with basic compounds.
Innovation Solution
A bilayer pharmaceutical tablet formulation is developed, with a first layer containing telmisartan dispersed in a dissolving tablet matrix and a second layer containing hydrochlorothiazide in a disintegrating matrix, using specific excipients and surfactants to enhance solubility and stability, allowing for immediate release and pH-independent dissolution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If telmisartan and hydrochlorothiazide are combined in a conventional fixed-dose combination using powder mixture or co-granulate, then the manufacturing process is simple, but the dissolution rate of hydrochlorothiazide is reduced and stability is compromised due to incompatibility with basic compounds
Solution Approach 1:
The tablet is divided into two distinct layers: a first layer containing telmisartan in a dissolving matrix, and a second layer containing hydrochlorothiazide in a disintegrating matrix. This segmentation physically separates the two drugs, preventing direct contact and chemical incompatibility while maintaining fixed-dose combination benefits. The layer structure allows each drug to be optimized independently for dissolution and stability.
Solution Approach 2:
A coating layer is applied to the hydrochlorothiazide particles before incorporation into the second tablet layer. This coating acts as an intermediary barrier that prevents direct interaction between hydrochlorothiazide and basic compounds in the telmisartan formulation, thereby maintaining stability while allowing controlled dissolution. The coating material is selected to be compatible with both drugs and to provide the necessary protective function.
2Reliability
If hydrochlorothiazide particles are coated with polymer solution to reduce contact area, then stability is improved, but the dissolution rate of hydrochlorothiazide is further reduced due to gel-forming properties
Solution Approach 1:
The coating parameters are carefully optimized to achieve the desired balance between stability and dissolution. The coating thickness, composition, and application method are controlled to provide sufficient protection against chemical incompatibility while maintaining adequate porosity and wettability for rapid drug release. The coating is designed to dissolve or disintegrate quickly in gastrointestinal conditions, ensuring immediate release of hydrochlorothiazide.
3Reliability
If separate film-coated tablets are filled into a capsule, then compatibility issues are avoided, but the dissolution rate of telmisartan is reduced due to lag-time effect of large capsule shells and patient compliance is compromised
Solution Approach 1:
The two separate drug formulations are merged into a single bilayer tablet structure, eliminating the need for capsule filling while maintaining drug compatibility through physical separation. The tablet design integrates both drugs in one dosage form, providing immediate release without lag-time effects and improving patient compliance through easier administration of a single tablet rather than multiple small tablets in a capsule.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bilayer tablet design improves the solubility and stability of telmisartan, ensures immediate release of hydrochlorothiazide, and overcomes compatibility issues, providing a reliable and effective fixed-dose combination with enhanced patient compliance.
Implementation Method 1
telmisartan dispersed in a dissolving tablet matrix comprising (a) a basic agent in a molar ratio of basic agent:telmisartan=1:1 to 10:1, (b) a surfactant or emulsifier in an amount of about 1 to 20 wt. % of the final composition
Implementation Method 2
a surfactant or emulsifier in an amount of about 1 to 20 wt. % of the final composition
Implementation Method 3
a second tablet layer containing a diuretic in a disintegrating tablet matrix
Data Source
AI summary
The invention relates to a bilayer pharmaceutical tablet comprising a first layer containing 3 to 50 wt. % of telmisartan dispersed in a dissolving tablet matrix and a second layer containing a diuretic in a disintegrating tablet matrix as well as a processes for producing same.